Evidence map›Paper›PMID 37483588›Full record

ArticleFrontiers in immunology2023

A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans.

Federico Rebaudi, Alfredo De Rosa, Marco Greppi, Roberto Pistilli, Resi Pucci, Flavio Andrea Govoni, Paolo Iacoviello, Francesco Broccolo, Giuseppe Tomasello, Silvia Pesce and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 2 countries.

Federico RebaudiDepartment of Experimental Medicine (DIMES), University of Genova, Genova, Italy.
Alfredo De RosaMultidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania "Luigi Vanvitelli", Napoli, Italy.
Marco GreppiDepartment of Experimental Medicine (DIMES), University of Genova, Genova, Italy.
Roberto PistilliOral and Maxillofacial Surgery, San Camillo-Forlanini Hospital, Roma, Italy.
Resi PucciOral and Maxillofacial Surgery, San Camillo-Forlanini Hospital, Roma, Italy.
Flavio Andrea GovoniOral and Maxillofacial Surgery, San Camillo-Forlanini Hospital, Roma, Italy.
Paolo IacovielloDepartment of Maxillofacial and Plastic Reconstructive Surgery, E.O. Ospedali Galliera, Genova, Italy.
Francesco BroccoloDepartment of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy.
Giuseppe TomaselloPrivate Practice, Lugano, Switzerland.
Silvia PesceDepartment of Experimental Medicine (DIMES), University of Genova, Genova, Italy.
Francesco LaganàIRCCS Ospedale San Martino, Unità Operativa Complessa di Chirurgia Maxillofacciale e Odontoiatra, Genova, Italy.
Bernardo BianchiIRCCS Ospedale San Martino, Unità Operativa Complessa di Chirurgia Maxillofacciale e Odontoiatra, Genova, Italy.
Francesca Di GaudioDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, CQRC (Quality Control and Chemical Risk) Hospital Company, Hospitals Reunited Villa Sofia Cervello, Palermo, Italy.
Alberto RebaudiPrivate Practice, President of Bio.C.R.A. (Biomaterials Clinical-Histological Research Association), Genova, Italy.
Emanuela MarcenaroDepartment of Experimental Medicine (DIMES), University of Genova, Genova, Italy.
Nini Hospital · LBOspedale Policlinico San Martino · ITUniversity of Genoa · ITEnte Ospedaliero Ospedali Galliera · ITItalian Association for Cancer Research · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Palermo · ITUniversity of Salento · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Oral squamous cell carcinoma (OSCC) accounts for approximately 90% of oral malignancies and has a 5-year mortality rate close to 50%. A consistent part (70%) of all oral cancers is diagnosed at an advanced stage since available screening techniques are ineffective. Therefore, it would be urgent to improve them. The diagnostic gold standard is tissue biopsy with histological and immunohistochemical assessment. This method presents some limitations. Biopsy is invasive and the histopathological evaluation is semi-quantitative, and the absolute abundance of the target cannot be reliably determined. In addition, tissue is highly processed and may lead to loss of information of the natural state. The search for classical and new clinical biomarkers on fragments of tissue/cells collected with a cytobrush is a highly hopeful technique for early detection and diagnosis of OSCC, because of its non-invasive sampling and easy collection method. Methods: Here we analyzed cytobrush biopsies samples collected from the oral cavity of 15 patients with already diagnosed OSCC by applying an innovative high-sensitivity ELISA technique, in order to verify if this approach may provide useful information for detection, diagnosis, and prognosis of OSCC. To this end, we selected six biomarkers, already used in clinical practice for the diagnosis of OSCC (EGFR, Ki67, p53) or selected based on recent scientific and clinical data which indicate their presence or over-expression in cells undergoing transformation and their role as possible molecular targets in immunecheckpoints blockade therapies (PD-L1, HLA-E, B7-H6). Results: The selected tumor biomarkers were highly expressed in the tumor core, while were virtually negative in healthy tissue collected from the same patients. These differences were highly statistically significant and consistent with those obtained using the gold standard test clearly indicating that the proposed approach, i.e. analysis of biomarkers by a custom ELISA technique, is strongly reliable. Discussion: These preliminary data suggest that this non-invasive rapid phenotyping technique could be useful as a screening tool for phenotyping oral lesions and support clinical practice by precise indications on the characteristics of the lesion, also with a view to the application of new anti-tumor treatments, such as immunotherapy, aimed at OSCC patients.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsMouth NeoplasmsBiomarkers, TumorEnzyme-Linked Immunosorbent AssayHumansPilot ProjectsSalivaSquamous Cell Carcinoma of Head and NeckBiomarkers, TumorcytobrushELISA immunoassayimmune checkpointsimmunotherapynatural killer cellsoral cancerscreeningtumor biomarkers

Identifiers

PMID37483588
PMCPMC10358763
OpenAlexW4383341422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.